Kristina Lång

Kristina Lång

Auto-generated profile, based on publicly available information

Kristina Lång

Diagnostic Radiology, Translational Medicine, Lund University, Malmö, Sweden

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in The Lancet Oncology
Verified
Journal Article
Closed access
KLKristina Lång
Kristina Lång
VJViktoria Josefsson
Viktoria Josefsson
ALAnna-Maria Larsson
Anna-Maria Larsson
SLStefan Larsson
Stefan Larsson
CHCharlotte Högberg
Charlotte Högberg
ARAldana Rosso
Aldana Rosso

1 May 2015 in European Radiology
Verified
Journal Article
Open access
PDF file
KLKristina Lång
Kristina Lång
IAIngvar Andersson
Ingvar Andersson
ARAldana Rosso
Aldana Rosso
ATAnders Tingberg
Anders Tingberg
PTPontus Timberg
Pontus Timberg
SZSophia Zackrisson
Sophia Zackrisson
Objective To assess the performance of one-view digital breast tomosynthesis (DBT) in breast cancer screening. Methods The Malmö Breast Tomosynthesis Screening Trial is a prospective population-based one-arm study with a planned inclusion of 15000 participants; a random sample of women aged 40–74 years eligible for the screening programme. This is an explorative analysis of the first half of the study population (n = 7500). Participants underwent one-view DBT and two-view digital mammography (DM), with independent double reading and scoring. Primary outcome measures were detection rate, recall rate and positive predictive value (PPV). McNemar's test with 95 % confidence intervals was used. Results Breast cancer was found in sixty-eight women. Of these, 46 cases were detected by both modalities, 21 by DBT alone and one by DM alone. The detection rate for one-view DBT was 8.9/1000 screens (95 % CI 6.9 to 11.3) and 6.3/1000 screens (4.6 to 8.3) for two-view DM (p < 0.0001). The recall rate after arbitration was 3.8 % (3.3 to 4.2) for DBT and 2.6 % (2.3 to 3.0) for DM (p < 0.0001). The PPV was 24 % for both DBT and DM. Conclusion Our results suggest that one-view DBT might be feasible as a stand-alone screening modality. Key Points • One-view DBT as a stand-alone breast cancer screening modality has not been investigated. • One-view DBT increased the cancer detection rate significantly. • The recall rate increased significantly but was still low. • Breast cancer screening with one-view DBT as a stand-alone modality seems feasible.

16 April 2019 in European Radiology
Verified
Journal Article
Open access
PDF file
ARAlejandro Rodriguez-Ruiz
Alejandro Rodriguez-Ruiz
KLKristina Lång
Kristina Lång
AGAlbert Gubern-Merida
Albert Gubern-Merida
JTJonas Teuwen
Jonas Teuwen
MBMireille Broeders
Mireille Broeders
RMRitse M. Mann
Ritse M. Mann
Purpose To study the feasibility of automatically identifying normal digital mammography (DM) exams with artificial intelligence (AI) to reduce the breast cancer screening reading workload. Methods and materials A total of 2652 DM exams (653 cancer) and interpretations by 101 radiologists were gathered from nine previously performed multi-reader multi-case receiver operating characteristic (MRMC ROC) studies. An AI system was used to obtain a score between 1 and 10 for each exam, representing the likelihood of cancer present. Using all AI scores between 1 and 9 as possible thresholds, the exams were divided into groups of low- and high likelihood of cancer present. It was assumed that, under the pre-selection scenario, only the high-likelihood group would be read by radiologists, while all low-likelihood exams would be reported as normal. The area under the reader-averaged ROC curve (AUC) was calculated for the original evaluations and for the pre-selection scenarios and compared using a non-inferiority hypothesis. Results Setting the low/high-likelihood threshold at an AI score of 5 (high likelihood > 5) results in a trade-off of approximately halving (− 47%) the workload to be read by radiologists while excluding 7% of true-positive exams. Using an AI score of 2 as threshold yields a workload reduction of 17% while only excluding 1% of true-positive exams. Pre-selection did not change the average AUC of radiologists (inferior 95% CI > − 0.05) for any threshold except at the extreme AI score of 9. Conclusion It is possible to automatically pre-select exams using AI to significantly reduce the breast cancer screening reading workload. Key Points • There is potential to use artificial intelligence to automatically reduce the breast cancer screening reading workload by excluding exams with a low likelihood of cancer. • The exclusion of exams with the lowest likelihood of cancer in screening might not change radiologists’ breast cancer detection performance. • When excluding exams with the lowest likelihood of cancer, the decrease in true-positive recalls would be balanced by a simultaneous reduction in false-positive recalls.

3 February 2025 in The Lancet Digital Health
Verified
Journal Article
Open access
VHVeronica Hernström
Veronica Hernström
VJViktoria Josefsson
Viktoria Josefsson
HSHanna Sartor
Hanna Sartor
DSDavid Schmidt
David Schmidt
ALAnna-Maria Larsson
Anna-Maria Larsson
KLKristina Lång
Kristina Lång
Emerging evidence suggests that artificial intelligence (AI) can increase cancer detection in mammography screening while reducing screen-reading workload, but further understanding of the clinical impact is needed. In this randomised, controlled, parallel-group, non-inferiority, single-blinded, screening-accuracy study, done within the Swedish national screening programme, women recruited at four screening sites in southwest Sweden (Malmö, Lund, Landskrona, and Trelleborg) who were eligible for mammography screening were randomly allocated (1:1) to AI-supported screening or standard double reading. The AI system (Transpara version 1.7.0 ScreenPoint Medical, Nijmegen, Netherlands) was used to triage screening examinations to single or double reading and as detection support highlighting suspicious findings. This is a protocol-defined analysis of the secondary outcome measures of recall, cancer detection, false-positive rates, positive predictive value of recall, type and stage of cancer detected, and screen-reading workload. This trial is registered at ClinicalTrials.gov, NCT04838756 and is closed to accrual. Between April 12, 2021, and Dec 7, 2022, 105 934 women were randomly assigned to the intervention or control group. 19 women were excluded from the analysis. The median age was 53·7 years (IQR 46·5-63·2). AI-supported screening among 53 043 participants resulted in 338 detected cancers and 1110 recalls. Standard screening among 52 872 participants resulted in 262 detected cancers and 1027 recalls. Cancer-detection rates were 6·4 per 1000 (95% CI 5·7-7·1) screened participants in the intervention group and 5·0 per 1000 (4·4-5·6) in the control group, a ratio of 1·29 (95% CI 1·09-1·51; p=0·0021). AI-supported screening resulted in an increased detection of invasive cancers (270 vs 217, a proportion ratio of 1·24 [95% CI 1·04-1·48]), wich were mainly small lymph-node negative cancers (58 more T1, 46 more lymph-node negative, and 21 more non-luminal A). AI-supported screening also resulted in an increased detection of in situ cancers (68 vs 45, a proportion ratio of 1·51 [1·03-2·19]), with about half of the increased detection being high-grade in situ cancer (12 more nuclear grade III, and no increase in nuclear grade I). The recall and false-positive rate were not significantly higher in the intervention group (a ratio of 1·08 [95% CI 0·99-1·17; p=0·084] and 1·01 [0·91-1·11; p=0·92], respectively). The positive predictive value of recall was significantly higher in the intervention group compared with the control group, with a ratio of 1·19 (95% CI 1·04-1·37; p=0·012). There were 61 248 screen readings in the intervention group and 109 692 in the control group, resulting in a 44·2% reduction in the screen-reading workload. The findings suggest that AI contributes to the early detection of clinically relevant breast cancer and reduces screen-reading workload without increasing false positives. Swedish Cancer Society, Confederation of Regional Cancer Centres, and Swedish governmental funding for clinical research.

1 November 2018 in The Lancet Oncology
Verified
Journal Article
Closed access
SZSophia Zackrisson
Sophia Zackrisson
KLKristina Lång
Kristina Lång
ARAldana Rosso
Aldana Rosso
KJKristin Johnson
Kristin Johnson
MDMagnus Dustler
Magnus Dustler
IAIngvar Andersson
Ingvar Andersson

2 September 2020 in European Radiology
Verified
Journal Article
Open access
PDF file
KLKristina Lång
Kristina Lång
MDMagnus Dustler
Magnus Dustler
VDVictor Dahlblom
Victor Dahlblom
AÅAnna Åkesson
Anna Åkesson
IAIngvar Andersson
Ingvar Andersson
SZSophia Zackrisson
Sophia Zackrisson
Objectives: To evaluate the potential of artificial intelligence (AI) to identify normal mammograms in a screening population. Methods: In this retrospective study, 9581 double-read mammography screening exams including 68 screen-detected cancers and 187 false positives, a subcohort of the prospective population-based Malmö Breast Tomosynthesis Screening Trial, were analysed with a deep learning–based AI system. The AI system categorises mammograms with a cancer risk score increasing from 1 to 10. The effect on cancer detection and false positives of excluding mammograms below different AI risk thresholds from reading by radiologists was investigated. A panel of three breast radiologists assessed the radiographic appearance, type, and visibility of screen-detected cancers assigned low-risk scores (≤ 5). The reduction of normal exams, cancers, and false positives for the different thresholds was presented with 95% confidence intervals (CI). Results: If mammograms scored 1 and 2 were excluded from screen-reading, 1829 (19.1%; 95% CI 18.3–19.9) exams could be removed, including 10 (5.3%; 95% CI 2.1–8.6) false positives but no cancers. In total, 5082 (53.0%; 95% CI 52.0–54.0) exams, including 7 (10.3%; 95% CI 3.1–17.5) cancers and 52 (27.8%; 95% CI 21.4–34.2) false positives, had low-risk scores. All, except one, of the seven screen-detected cancers with low-risk scores were judged to be clearly visible. Conclusions: The evaluated AI system can correctly identify a proportion of a screening population as cancer-free and also reduce false positives. Thus, AI has the potential to improve mammography screening efficiency. Key Points: • Retrospective study showed that AI can identify a proportion of mammograms as normal in a screening population. • Excluding normal exams from screening using AI can reduce false positives.